Altimmune (ALT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$121.9 million.

  • Altimmune's Net Cash Flow fell 37506.72% to -$121.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 15374.14%. This contributed to the annual value of -$98.2 million for FY2024, which is 50866.53% down from last year.
  • Per Altimmune's latest filing, its Net Cash Flow stood at -$121.9 million for Q3 2025, which was down 37506.72% from $134.0 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Net Cash Flow peaked at $134.0 million during Q2 2025, and registered a low of -$121.9 million during Q3 2025.
  • Over the past 5 years, Altimmune's median Net Cash Flow value was -$6.4 million (recorded in 2023), while the average stood at -$2.9 million.
  • In the last 5 years, Altimmune's Net Cash Flow surged by 137090.11% in 2021 and then crashed by 120289.09% in 2022.
  • Quarter analysis of 5 years shows Altimmune's Net Cash Flow stood at $15.4 million in 2021, then crashed by 206.03% to -$16.4 million in 2022, then skyrocketed by 394.86% to $48.3 million in 2023, then crashed by 88.7% to $5.5 million in 2024, then crashed by 2335.31% to -$121.9 million in 2025.
  • Its last three reported values are -$121.9 million in Q3 2025, $134.0 million for Q2 2025, and $12.2 million during Q1 2025.